RC morbidity, identifying fragile pts at risk of post operative complications and their severity. Further analyses are necessary to confirm the data obtained from this preliminary study. (Funt et al ASCO 2016). We hypothesized that T cell repertoire is more clonal in tumors than in benign inflammation.
INTRODUCTION AND OBJECTIVES: High T cell receptor (TCR) repertoire clonality is associated with clinical response to immune checkpoint blockade in bladder cancer (Funt et al ASCO 2016) . We hypothesized that T cell repertoire is more clonal in tumors than in benign inflammation.
METHODS: After obtaining IRB approval, we prospectively identified n¼12 patients with bladder lesions at Montefiore Medical Center undergoing transurethral resection. Specimens were collected at time of transurethral resection and frozen and stored at -80C. DNA was extracted and high throughput DNA sequencing of the CDR3 region of the TCR beta chain using the immunoSEQ assay (Adaptive Biotechnologies) was performed. T cell fraction, clonal dominance, and maximum frequency of TCR clone were assessed.
RESULTS: There was an even distribution of specimens across all pathologic stages: 3/12 were T0, 3/12 were Ta, 3/12 were T1, and 3/ 12 were T2 or greater. The median number of productive TCR rearrangements sequenced in each sample in urothelial carcinoma specimens (UCþ) and benign (UC-) specimens was 5,569 and 25,872 respectively. The median number of unique TCR rearrangements sequenced in UCþ and UC-specimens was 3,069 and 9,680, respectively. The median tumor infiltrating lymphocyte (TIL) percentage in UCþ and UC-specimens was 2% and 12%, respectively. The UCþ specimens demonstrated clonality as evidenced by identification of a specific T cell clone being present in up to 17% of the total TIL pool; in contrast, the frequency of the max T cell clone was 2% in UC-specimens ( Figure 1) .
CONCLUSIONS: Primary urothelial tumors contain clonally expanded T cell populations that are not present in benign urothelial inflammation. These data support the hypothesis that bladder tumors induce an antigen driven immunogenic host response, in contrast to the benign inflammatory response, which does not appear to demonstrate any T cell clonal dominance. Future studies should be aimed to validate these results and to identify which tumor derived antigens are of clinical significance. of all bladder cancers. Urothelial cells are continuously in relation with several signal molecules and neurotransmitters. One of these, muscarinic acetyl choline receptors, are expressed on both urothelial cells and detrusor muscle and play a great role in human bladder physiology. Specifically M2 and M3 type receptors are the most common receptors of bladder. M2 receptors are specially found on umbrella cells on the mucosa layer of bladder and almost up to three times more frequent than M3 receptors. Some of the recent studies show the importance and role of muscarinic receptors on some types of disease. In this study muscarinic receptor expression, namely M2 and M3 subtypes of muscarinic receptors were analyzed on bladder tumor samples.
Source of
METHODS: In order to have a strong evidence of M2 and M3 subtypes in bladder tumors, the samples were analyzed both with Western blot technique and with immunohistochemistry. Bladder tumor samples, which are collected by transurethral resection of the bladder, are homogenized, centrifuged and preserved at -80?C. Protein component was analyzed via Lowry method. p< 0.05 data were accepted as statistically significant. The samples also were analyzed by pathologists with immunohistochemistry technique for M2 and M3 muscarinic receptor expression.
RESULTS: Data of 45 patients were analyzed. Statistical analyses show that patients with pathological T2 stage and with progressed disease during follow-up have greater M2 receptor value which is statistically significant. There was no relation between M3 muscarinic receptor level and tumor grade/stage or progression rate. These results were not dependent by patient age or lower urinary tract symptoms. Progression rate was found higher in patients with higher M2 muscarinic receptor levels on bladder tissue samples.
CONCLUSIONS: M2 and M3 muscarinic receptors not only play a great role on bladder functions but also also may be important for bladder cancer pathophysiology though, their role in the development of blader cancer has not been defined yet. This current trial may indicate M2 receptors to be a potential treatment target for bladder cancer.
Source of Funding: This study was supported by Marmara University Scientific Research Programme (SAG-C-TUP 100216-0034).
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